Asia Pacific Medical Oxygen Concentrators Market

Asia Pacific Medical Oxygen Concentrators Market Size

The Asia Pacific Medical Oxygen Concentrators Market was worth USD 0.83 billion in 2024. The Asia Pacific market is expected to reach USD 1.60 billion by 2033 from USD 0.90 billion in 2025, rising at a CAGR of  7.51% from 2025 to 2033.

The Asia Pacific medical oxygen concentrators market is driven by rising respiratory health concerns, aging populations and increased demand for home-based care which involves the production as well as distribution and application of devices that extract oxygen from ambient air for therapeutic use. These machines are essential for patients suffering from chronic respiratory conditions such as Chronic Obstructive Pulmonary Disease (COPD), pneumonia and other ailments that impair oxygen intake. As healthcare systems in the region grapple with a rising disease burden and an aging population so demand for home-based and clinical oxygen therapy solutions has surged. The market is further catalyzed by post-pandemic awareness regarding respiratory health and emergency preparedness. Several countries in the region experienced acute oxygen shortages during the second wave of the pandemic thereby prompting governments and private players to invest heavily in oxygen infrastructure. In 2023, India alone imported over 150,000 units of medical oxygen concentrators amid surging domestic needs.

MARKET DRIVERS

Rising Prevalence of Respiratory Diseases in the Region

The escalating prevalence of chronic respiratory diseases across the region is one of the primary drivers fueling the growth of the Asia Pacific medical oxygen concentrators market. Countries such as India, China and Indonesia are witnessing a sharp increase in cases of COPD, asthma, tuberculosis and lung cancer which are largely attributed to rising pollution levels, smoking habits and occupational exposure to harmful particulates. Respiratory diseases accounted for over 2.4 million deaths in the Asia Pacific region which marked a 19% increase compared to data from 2010. In China, more than 100 million individuals suffer from COPD making it one of the largest patient pools globally. Similarly, India reported over 30 million COPD cases in 2022. This growing health burden necessitates long-term oxygen therapy thereby increasing reliance on portable and stationary oxygen concentrators. Additionally, heightened public awareness campaigns and government initiatives aimed at early diagnosis have expanded treatment access in rural areas where hospital-based care remains limited.

Aging Population and Increased Geriatric Dependency on Oxygen Therapy

Aging population and increased geriatric dependency on oxygen therapy are key factors driving the Asia Pacific medical oxygen concentrators market whereas older adults are more prone to respiratory illnesses and chronic conditions that necessitate long-term oxygen support. The Asia Pacific region is home to nearly 60.79% of the world’s elderly population aged 60 years or above with Japan, South Korea and Thailand leading in terms of proportion of elderly citizens. In Japan, over 30.58% of the total population is aged 65 or older which increases the demand for home healthcare equipment including medical oxygen concentrators. Moreover, age-related decline in lung function often results in chronic hypoxemia which mandates continuous oxygen support.By 2050, the number of people aged 60 and above in Asia will double thus reaching nearly 2.5 billion. This demographic transition is expected to significantly widen the base of users dependent on oxygen therapy. Consequently, manufacturers are enhancing product portfolios to include lightweight and energy-efficient models tailored for geriatric home care environments in remote and underserved regions.

MARKET RESTRAINTS

High Cost of Advanced Oxygen Concentrator Devices

High cost of advanced oxygen concentrator devices remains a key restraint to the expansion of the Asia Pacific market. Especially for models featuring pulse-dose delivery, remote monitoring capabilities and extended battery life which may be unaffordable for many end users without financial assistance.These premium devices often range between USD 1,000 to USD 3,000 per unit placing them beyond the reach of many middle and low-income households. The population in Southeast Asia faces financial barriers to accessing home-based medical equipment in the absence of insurance coverage or government support. In countries like Vietnam and the Philippines, out-of-pocket healthcare expenses account for more than 50.84% of total health spending thereby discouraging patients from purchasing high-end oxygen concentrators. Additionally, despite growing awareness and reimbursement policies for oxygen therapy equipment remain fragmented across the region. For instance, Australia has a well-established Medicare rebate system for eligible patients while nations such as Indonesia and Cambodia offer minimal or no financial assistance. This disparity hampers widespread adoption and limits market penetration in rural and semi-urban areas where healthcare budgets are constrained.

Regulatory Hurdles and Quality Control Complexities

Regulatory complexities and stringent quality control standards present another critical barrier to the growth of the Asia Pacific medical oxygen concentrators market. Each country in the region maintains its own set of regulatory frameworks which often lead to delays in product approvals and market entry for international manufacturers. For example, the Therapeutic Goods Administration (TGA) in Australia and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan enforce rigorous testing and certification protocols for medical-grade oxygen concentrators while increasing time-to-market. Only 30.39% of participating economies had fully aligned their regulatory processes for respiratory equipment as of 2023. Furthermore, the influx of substandard or counterfeit oxygen concentrators in emerging markets such as Myanmar and Nepal has prompted authorities to impose stricter compliance measures. These challenges not only elevate operational costs for genuine manufacturers but also erode consumer confidence thereby restraining overall market momentum.

MARKET OPPORTUNITIES

Expansion of Telehealth and Home Healthcare Infrastructure

The burgeoning telehealth ecosystem and the parallel development of home healthcare infrastructure in the Asia Pacific region are opening new avenues for growth in the medical oxygen concentrators market. Governments and private healthcare providers across the region are increasingly investing in decentralized care models to reduce the burden on overstrained hospital systems. In Singapore, the Ministry of Health launched the “Home Oxygen Therapy Program” to enable patients with chronic lung diseases to receive oxygen therapy at home under remote supervision. Similarly, in India the Ayushman Bharat Digital Mission is integrating telemonitoring platforms with home diagnostic tools including oxygen concentrators which are used to enhance post-discharge care efficiency. Portable and smart-connected oxygen concentrators are gaining traction due to their compatibility with remote diagnostics and real-time monitoring systems. The adoption of IoT-enabled medical devices in the Asia Pacific region is expected to rise by 25.06% annually by directly influencing the demand for technologically advanced oxygen concentrators tailored for home use.

Government Initiatives and Public-Private Partnerships

Governments across the Asia Pacific region are increasingly collaborating with private entities to strengthen domestic oxygen generation and distribution capabilities by following the disruptions caused by the global pandemic. Several national health ministries have introduced funding schemes and procurement programs aimed at expanding access to oxygen concentrators in both urban and rural settings. For instance, the Australian Department of Health announced an AUD 80 million investment in 2023 to upgrade state-level oxygen supply chains and procure additional concentrators for community health centers. In Bangladesh, the Directorate General of Health Services partnered with NGOs and international agencies to distribute over 10,000 oxygen concentrators in district hospitals and upazila-level health complexes. China’s National Medical Products Administration has also streamlined approval processes for domestic manufacturers producing ISO-certified oxygen concentrators thereby providing tax exemptions and subsidies to boost production capacity. These initiatives not only address immediate healthcare gaps but also lay the foundation for sustainable market expansion by fostering trust and affordability among end-users.

MARKET CHALLENGES

Supply Chain Disruptions and Component Shortages

Supply chain instability remains a formidable challenge for the Asia Pacific medical oxygen concentrators market due to the global semiconductor shortages and geopolitical tensions affecting raw material availability. Many components essential for manufacturing oxygen concentrators such as pressure sensors, compressors and molecular sieves are sourced from a limited number of suppliers who are primarily based in North America and Europe. The lead time for critical electronic components used in oxygen concentrators increased by 40.98% compared to pre-pandemic levels. This delay has directly impacted production schedules and inventory management for regional manufacturers. In countries like Malaysia and Thailand where prolonged disruptions in logistics networks are caused by port congestion and labor shortages further exacerbate delivery bottlenecks. Over 30.71% dip in domestic production volumes in early 2023 due to the unavailability of imported parts. These constraints not only inflate device prices but also hinder timely distribution in crisis-hit or remote locations where urgent oxygen support is required.

Limited Awareness and Low Adoption Rates in Rural Areas

Despite rising healthcare investments, awareness and adoption of medical oxygen concentrators remain alarmingly low in rural and semi-urban areas across the Asia Pacific region. Cultural misconceptions as well as a lack of physician education on oxygen therapy and insufficient training for caregivers contribute to poor utilization rates. In rural parts of Indonesia and Papua New Guinea less than 15.7% of surveyed households were aware of the benefits of oxygen concentrators and fewer than 5.2% had access to one. Irregular power supply persists in over 30.91% of households even in electrified villages. To combat this, some manufacturers are introducing solar-powered models but they remain niche and expensive. The gap between urban and rural adoption will continue to limit the market’s full potential without comprehensive awareness campaigns and infrastructural upgrades.

SEGMENTAL ANALYSIS

By Modality Insights

The stationary segment dominated the Asia Pacific medical oxygen concentrators market by capturing 58.09% in 2024. This dominance is primarily attributed to their widespread use in clinical environments such as hospitals, intensive care units and long-term care facilities where uninterrupted oxygen supply is critical. Hospital bed density in countries like South Korea and Japan exceeds 12 beds per 1,000 population which is significantly higher than the global average and escalates the demand for permanent oxygen infrastructure. Additionally, government policies mandating adequate ICU preparedness have further boosted procurement volumes. In China, the National Health Commission mandated in 2023 that all secondary-level hospitals must be equipped with at least one high-flow stationary concentrator which directly influences national adoption rates. Furthermore, these devices offer higher oxygen output and prolonged operational capacity compared to portable counterparts while making them indispensable in emergency and post-operative scenarios where stable delivery is essential.

The portable segment is projected to witness the fastest CAGR of 14.91% during the forecast period and is driven by rising home healthcare adoption and patient preference for mobility. As urbanization accelerates and disposable incomes increase in India and Southeast Asian nations which more patients are opting for home-based oxygen therapy. The home healthcare sector in APAC grew by 12.6% in 2023 with oxygen therapy being among the top three home treatments. Moreover, technological advancements such as lightweight lithium-ion batteries and pulse-dose delivery functions have enhanced usability and compliance. Over 7 million patients received outpatient oxygen therapy in 2022 which many are using portable devices. Additionally, governments in Australia and Singapore are promoting portable concentrators through insurance coverage and telehealth integration programs thus further accelerating consumer uptake and reinforcing the segment’s growth trajectory.

By Technology Insights

The continuous flow technology segment held the leading share of 62.6% of the Asia Pacific medical oxygen concentrators market in 2024 due to its suitability for patients requiring constant and high-volume oxygen supply. These devices deliver a steady stream of oxygen irrespective of the patient's breathing pattern while making them ideal for nocturnal use as well as acute care and chronic conditions like COPD. Over 200 million individuals across Asia suffer from COPD with continuous flow concentrators forming the cornerstone of long-term management. Hospitals in China also prefer this modality for ICU settings where precise oxygen titration is required. The continuous flow segment remains dominant in both institutional and homecare applications with aging populations and increasing nocturnal hypoxemia cases.

The pulse flow technology segment is anticipated to witness the highest CAGR of 15.03% between 2025 to 2033 owing to its efficiency and portability. Pulse flow concentrators release oxygen only during inhalation thus conserving energy and extending battery life which are critical advantages for active users. New oxygen concentrator purchases in urban India were pulse dose models due to rising consumer awareness and improvements in sensor-based triggering mechanisms. Additionally, manufacturers such as Yuwell and Inogen have expanded distribution networks in Southeast Asia while offering cost-effective mobile units tailored for ambulatory patients. Rural physicians now prescribe portable pulse flow devices for patients with mild-to-moderate respiratory insufficiency. Government-backed health schemes in Thailand and Malaysia have also included pulse flow models under subsidized categories which further fuels demand and cementing this segment’s rapid expansion.

By End-User Insights

The hospitals segment was the largest segment and held 65.71% of the total Asia Pacific medical oxygen concentrators market share in 2024 and is driven by the critical need for a reliable oxygen supply in emergency and intensive care settings. Hospital-based procurement has surged with the region’s public health infrastructure expanding to accommodate growing disease burdens. China alone added over 200,000 hospital beds between 2021 and 2023 many of which were equipped with centralized or auxiliary oxygen concentrators. In India, the Ministry of Health launched the "Oxygen Strengthening Initiative" in 2022 thereby allocating INR 2,000 crores to upgrade oxygen generation and supply systems across district hospitals thus leading to a spike in device installations. Additionally, the rise in surgical procedures and post-COVID rehabilitation centers has increased demand for oxygen support.

The home care segment is likely to experience the fastest CAGR of 13.5% from 2025 to 2033. The pandemic catalyzed a shift toward decentralized care models which encouraged the use of home-based oxygen therapy to alleviate hospital overcrowding. Home oxygen therapy usage in the country rose by 18.29% year-on-year which is supported by better Medicare coverage and digital health integration. In Singapore, the Ministry of Health introduced subsidies covering up to 75.7% of portable oxygen concentrator costs for elderly patients suffering from chronic lung diseases. Similarly, telemedicine platforms in Indonesia and Vietnam have partnered with medical device providers to facilitate remote monitoring and home deliveries of oxygen therapy equipment. The number of home oxygen users in India crossed 1.2 million in 2023 and is driven by private insurer participation and falling device prices which signal robust future growth for the home care segment.

REGIONAL ANALYSIS

China outperformed other regions in the Asia Pacific medical oxygen concentrators market in 2024 by accounting for 28.69% of the share 2024. The country is both a major producer and consumer of medical oxygen concentrators with companies like Yuwell Medical and Air Liquide Healthcare playing pivotal roles in local production and international exports. Over 100 million individuals suffer from chronic respiratory diseases which creates sustained demand for oxygen therapy. In response, the government upgraded healthcare infrastructure under the “Healthy China 2030” blueprint, which included provisions for oxygen supply in every county hospital.

India was positioned second in holding the dominant share of the Asia Pacific medical oxygen concentrators market. The surge in demand is driven by a combination of rising respiratory disease prevalence and an aging population along with increased access to affordable home oxygen therapy. COPD affects over 30 million people nationwide thereby contributing to the high incidence of long-term oxygen dependency. During the second wave of the pandemic India faced acute oxygen shortages, thereby prompting both governmental and private initiatives to bolster supply chains. Further, local manufacturing incentives under the Production Linked Incentive (PLI) scheme have attracted new entrants which enhance availability and affordability across Tier-II and Tier-III cities.

Japan’s medical oxygen concentrators market growth is driven by mature healthcare infrastructure, a high geriatric population and extensive adoption of home-based oxygen therapy. With over 30.5% of its population aged above 65 Japan faces significant demand for chronic disease management solutions including continuous oxygen support. More than 1.5 million patients receive long-term oxygen therapy with most relying on either stationary or portable concentrators. The country’s universal health insurance system covers up to 90.7% of oxygen therapy costs thereby fostering widespread accessibility. Additionally, Japanese manufacturers such as Panasonic and Respironics maintain a strong presence in the domestic market while focusing on compact and energy-efficient models suited for elderly users.

Australia’s medical oxygen concentrators market is likely to have significant growth opportunities during the forecast period and is distinguished by its well-developed healthcare ecosystem along with favorable reimbursement mechanisms. The country’s Therapeutic Goods Administration (TGA) ensures stringent quality standards for imported and locally produced concentrators thereby ensuring patient safety. Over 700,000 individuals suffer from asthma and COPD thus necessitating regular oxygen therapy interventions. Medicare provides rebates for eligible patients purchasing or renting oxygen concentrators reducing out-of-pocket expenses. In 2023, the Australian Department of Health allocated AUD 80 million to enhance community-based oxygen supply chains in rural and remote areas.

South Korea’s medical oxygen concentrators market growth is driven by its emphasis on technological innovation and digital healthcare integration. The country’s aging population and high incidence of respiratory ailments drive consistent demand for oxygen concentrators. Over 15.2% of the population is aged 65 or older with age-related chronic illnesses rising sharply. The Ministry of Food and Drug Safety mandates rigorous product certifications but encourages innovation through fast-track approvals for IoT-enabled devices. Samsung Medison and other local firms have developed smart oxygen concentrators compatible with AI-based health monitoring apps. A 2023 study by the Korean Society of Pulmonology found that over 80.17% of surveyed hospitals had upgraded to digital oxygen management systems which indicates a growing trend toward connected devices.

The competition in the Asia Pacific medical oxygen concentrators market is marked by a blend of global leaders and rapidly growing regional manufacturers vying for market share through innovation, pricing strategies and enhanced distribution networks. While multinational corporations leverage their established brand reputation and technological expertise because of which domestic players capitalize on cost-efficiency and localized supply chains to strengthen their presence. The market landscape is fragmented with several companies striving to meet the rising demand driven by increasing respiratory disease prevalence and post-pandemic healthcare reforms. Product differentiation through design along with portability and digital integration has become a key battleground as firms seek to cater to both institutional and homecare users. Additionally, regulatory challenges and varying reimbursement policies across countries necessitate adaptive business models. As governments continue to invest in healthcare infrastructure because of which these companies are expanding their footprints through strategic collaborations, acquisitions and localized manufacturing facilities to gain a competitive edge.

KEY MARKET PLAYERS AND COMPETITIVE LANDSCAPE

Inogen Inc., Philips (Koninklijke Philips N.V.), CAIRE Inc., Nidek Medical Products Inc., Invacare Corporation, ResMed Inc., Teijin Limited, DeVilbiss Healthcare LLC, GCE Group, O2 Concepts LLC, Linde plc, Air Liquide, Yuyue Medical, Haier, Longfian Scitech Co., Ltd., Canta Medical, AERTI, Omron Healthcare, Drägerwerk AG & Co. KGaA, and Apex Medical (now Wellell) are some of the key market players in the Asia Pacific medical oxygen concentrators market.

The competition in the Asia Pacific medical oxygen concentrators market is marked by a blend of global leaders and rapidly growing regional manufacturers vying for market share through innovation, pricing strategies and enhanced distribution networks. While multinational corporations leverage their established brand reputation and technological expertise because of which domestic players capitalize on cost-efficiency and localized supply chains to strengthen their presence. The market landscape is fragmented with several companies striving to meet the rising demand driven by increasing respiratory disease prevalence and post-pandemic healthcare reforms. Product differentiation through design along with portability and digital integration has become a key battleground as firms seek to cater to both institutional and homecare users. Additionally, regulatory challenges and varying reimbursement policies across countries necessitate adaptive business models. As governments continue to invest in healthcare infrastructure because of which these companies are expanding their footprints through strategic collaborations, acquisitions and localized manufacturing facilities to gain a competitive edge.

Top Players in the Asia Pacific Medical Oxygen Concentrators Market

Philips (Netherlands-based)

Philips is a dominant global player with a strong foothold in the Asia Pacific medical oxygen concentrators market. The company offers technologically advanced oxygen therapy solutions tailored for both hospital and home care settings. Its commitment to integrating digital health technologies into respiratory care has positioned it as a preferred choice among healthcare providers across the region. In countries like China, India and Australia Philips collaborates with local governments and distributors to enhance the accessibility of oxygen concentrators. Philips continues to drive adoption across diverse clinical environments in the Asia Pacific by focusing on user-friendly designs and remote patient monitoring capabilities.

ResMed (United States-based)

ResMed plays a significant role in shaping the Asia Pacific medical oxygen concentrators market through its innovative approach to sleep-disordered breathing and chronic respiratory conditions. The company's devices are widely used across hospitals and homecare settings in Japan, South Korea and Australia due to their efficiency and reliability. ResMed emphasizes integrated care models that combine oxygen therapy with cloud-connected platforms thereby allowing real-time monitoring and improved patient outcomes. The company has successfully expanded into emerging markets such as India and Indonesia with a strong distribution network and localized service support. Its focus on sustainability and energy-efficient designs aligns with regional healthcare trends thereby reinforcing its competitive presence and long-term growth potential.

Yuwell Medical (China-based)

Yuwell Medical holds considerable influence in the Asia Pacific medical oxygen concentrators market particularly within China and neighboring Southeast Asian countries. The company produces a wide range of oxygen concentrators from entry-level stationary units to high-end portable models suited for home use. Yuwell benefits from cost-effective manufacturing and government-backed initiatives that promote indigenous production of medical equipment. Its affordability and widespread availability have made it a go-to brand for public hospitals and rural health centers. Additionally, Yuwell’s aggressive expansion strategy includes partnerships with e-commerce platforms and telehealth providers to enhance last-mile delivery.

Top Strategies Used by Key Market Participants

Product innovation and technological integration are one of the primary strategies adopted by key players in the Asia Pacific medical oxygen concentrators market. Companies are increasingly incorporating smart features such as IoT-based monitoring, mobile connectivity and low-power consumption mechanisms to cater to evolving consumer needs. These advancements not only improve patient compliance but also facilitate remote diagnostics thereby enhancing overall treatment efficacy across diverse healthcare environments.

Another crucial strategy is expanding distribution networks and strengthening local partnerships. Leading manufacturers are collaborating with regional distributors, pharmacies and e-commerce platforms to ensure wider reach especially in underserved areas. These efforts are complemented by after-sales services and training programs for caregivers which further boost device adoption and customer retention.

Companies are investing heavily in regulatory compliance and quality assurance to maintain credibility and accelerate market access. By securing certifications and adhering to international standards, firms can streamline approvals across different countries thereby ensuring product consistency and building trust among healthcare institutions and end-users alike.

REGIONAL ANALYSIS

• In January 2023, Philips launched a new line of digitally integrated oxygen concentrators in China which is designed to seamlessly connect with remote patient monitoring systems.
• In May 2023, ResMed expanded its distribution network in India by partnering with leading e-commerce platforms to enhance the accessibility of home-use oxygen concentrators.
• In September 2023, Yuwell Medical entered into a strategic collaboration with local telemedicine providers in Indonesia to offer bundled oxygen therapy solutions for homecare patients.
• In February 2024, Panasonic introduced a solar-powered portable oxygen concentrator in select markets across the Asia Pacific region.
• In August 2024, CareFusion, a division of Becton Dickinson announced a joint venture with a Japanese healthcare technology firm to develop AI-enabled oxygen concentrators tailored for elderly patients.

MARKET SEGMENTATION

This research report on the Asia Pacific medical oxygen concentrators market is segmented and sub-segmented into the following categories.

By Product Type

• Stationary Concentrators
• Portable Concentrators

By Technology

• Continuous Flow
• Pulse Flow

By End-User

• Hospitals
• Home Care
• Ambulatory Surgical Centers

By Country

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC